Oncophage

Mount Sinai Researchers Discover How to Boost Efficacy of Vaccine Designed to Prevent Melanoma Recurrence

Retrieved on: 
Monday, November 16, 2020
Medicine, Clinical medicine, Medical specialties, Vaccination, Vaccines, Cancer vaccines, Cancer vaccine, Vaccine, Melanoma, Oncophage, Herpes simplex research

These results are important because most cancer vaccine trials have failed to show clinical efficacy.

Key Points: 
  • These results are important because most cancer vaccine trials have failed to show clinical efficacy.
  • Sixty patients who had stage 2 or 3 melanoma, and whose cancer was successfully removed via surgery, received the vaccine.
  • Half of the patients received the vaccine alone while the other half received the vaccine with Flt3L and poly-ICLC.
  • Researchers also plan to follow trial participants over time and measure how many have cancer recurrence to further study the vaccine's efficacy in each group.

Pepscan Produces Clinical Peptides for Innovative Personalized Cancer Vaccine Trial

Retrieved on: 
Tuesday, June 25, 2019
Vaccination, Medicine, Clinical medicine, Medical specialties, Cancer vaccines, Cancer vaccine, Vaccine, Experimental cancer treatments, Oncophage, Tumor antigen vaccine

LELYSTAD, Netherlands, June 25, 2019 /PRNewswire/ --Pepscan has positioned itself as a critical partner in a collaborative clinical trial with personalized anti-cancer vaccines.

Key Points: 
  • LELYSTAD, Netherlands, June 25, 2019 /PRNewswire/ --Pepscan has positioned itself as a critical partner in a collaborative clinical trial with personalized anti-cancer vaccines.
  • In this trial, Pepscan is solely responsible for production of clinical neoantigen peptides, tailored to tumors of individual patients.
  • "Our crucial contribution to this clinical trial establishes us as a key supplier of peptide technologies in the cancer vaccine field."
  • The company offers her expertise to new personalized cancer vaccine initiatives now, contributing to new avenues towards personalized cancer treatment.

Peloton Therapeutics Announces Clinical Data Update for PT2977 at European International Kidney Cancer Symposium

Retrieved on: 
Monday, April 1, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Science, Clinical medicine, Medicine, Cancer, Genodermatoses, Syndromes, Von Hippel–Lindau disease, Von Hippel–Lindau tumor suppressor, Endolymphatic sac tumor, Oncophage

Peloton Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced today the presentation of data from the Phase 2 portion of the companys Phase 1/2 clinical trial of its lead drug candidate, PT2977, at the Fourteenth European International Kidney Cancer Symposium in Dubrovnik, Croatia.

Key Points: 
  • Peloton Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced today the presentation of data from the Phase 2 portion of the companys Phase 1/2 clinical trial of its lead drug candidate, PT2977, at the Fourteenth European International Kidney Cancer Symposium in Dubrovnik, Croatia.
  • The Phase 1 portion included a once daily administration schedule dose escalation cohort of 37 patients with advanced solid tumors.
  • PT2977 has demonstrated anti-tumor activity with a favorable safety profile in an early-stage clinical study in patients with solid tumors.
  • Peloton is also currently evaluating PT2977 in an international Phase 2 trial in von Hippel-Lindau (VHL) disease-associated RCC.